NORTH CHICAGO, Ill., Feb. 19, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen and Company 34^th Annual Health Care Conference on Wednesday, March 5, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 7:40 a.m. Central time.

NORTH CHICAGO, Ill., Feb. 5, 2014 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) announces a US$320 million [approximately S$400 million] investment to establish operations in Singapore for small molecule and biologics active drug substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie's oncology and immunology pipeline to serve markets globally.

NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie's investigational all-oral, interferon-free therapy with and without ribavirin (RBV) in patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. These results described below confirm previously reported AbbVie data and further demonstrate high sustained virologic response rates 12 weeks post treatment (SVR₁₂) and tolerability in these GT1 patients.

NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer.  The three-arm trial will compare the addition of veliparib plus carboplatin or placebo plus carboplatin to standard neoadjuvant chemotherapy. 

NORTH CHICAGO, Ill., Jan. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2013 financial results on Friday, Jan. 31, 2014, before the market opens.

NORTH CHICAGO, Ill., Dec. 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 32^nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 11 a.m. Central time.

NORTH CHICAGO, Ill., Dec. 10, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with chronic, genotype 1 (GT1) hepatitis C virus (HCV) infection. In the 394-patient SAPPHIRE-II study, 96 percent of patients who previously failed pegylated interferon and ribavirin treatment, including approximately 49 percent of who were prior null responders, achieved sustained virologic response at 12 weeks (SVR₁₂) with the regimen. The majority of patients were GT1a, considered a difficult-to-treat subtype, and the SVR₁₂ rates of GT1a and GT1b were 96 percent and 97 percent, respectively. Virologic relapse or breakthrough was noted in 2 percent of patients receiving the 3D regimen plus ribavirin. In addition, the discontinuation rate due to adverse events was 1 percent.

NORTH CHICAGO, Ill., Nov. 26, 2013 /PRNewswire/ -- In advance of World AIDS Day on December 1, 2013, AbbVie (NYSE: ABBV) today announced the launch of See Us: Women Take a Stand on HIV, an international awareness campaign focused on helping to address the unique challenges faced by women living with HIV. The campaign is being launched in collaboration with an expert steering committee, which includes representation from women living with and affected by HIV, the medical community, the International Association of Providers in AIDS Care (IAPAC), and NAM/aidsmap, the HIV information charity.

NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved a sustained virologic response at 12 weeks post-treatment (SVR₁₂) of 96 percent. The majority of patients were GT1a, considered the more difficult-to-treat subtype, and the SVR₁₂ rates of GT1a and GT1b were 95 percent and 98 percent, respectively. The rate of virologic relapse or breakthrough was low, occurring in 1.7 percent of patients receiving the 3D regimen. In addition, discontinuation rates due to adverse events were low, and of an equal percentage (0.6 percent) in both active and placebo groups.